FDAnews Drug Daily Bulletin

FDA Accepts Rituxan Biosimilar for Review

Sept. 15, 2017

The FDA has accepted Sandoz’ application for approval of its rituximab biosimilar to Rituxan.

Rituxan treats cancers of the blood, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis.

Rituxan is a Biogen brand jointly marketed by Biogen and Genentech USA.

View today's stories